The recent discovery by researchers at Memorial Sloan Kettering Cancer Center (MSK) has shed new light on the intricate mechanisms of colorectal cancer's ability to spread and resist treatment. The focus is on a protein called ZFP36L2, which acts as a 'molecular switch' linking the gut's damage-sensing system to the ability of cells to shift identities for repair. This protein is crucial in both normal tissue repair and cancer cell metastasis, making it a potential target for new treatments.
The study reveals that ZFP36L2 is essential for cells to detect damage and turn on stem cell renewal programs. When injury occurs, mature cells receive an emergency signal to revert to a stem cell state, but this transition is regulated by ZFP. It clears the alarm signal, allowing cells to complete their journey back to a stem cell state and begin rebuilding. This process is critical for both healthy gut repair and cancer cell metastasis.
In cancer, ZFP36L2's role is twofold. It helps cancer cells spread by turning off the stress response and rewinding them into a stem cell-like state. However, when ZFP is lost in a primary tumor, it can also contribute to treatment resistance. Tumors without ZFP tend to grow more slowly but shift into aggressive, treatment-resistant types, making them harder to treat.
The research team's findings suggest that disrupting ZFP in metastatic cancer cells could compromise their ability to start new tumors in other parts of the body. This opens up the possibility of using ZFP to make tumors self-destruct by rapidly overwhelming cancer cells before they can adapt. Additionally, identifying patients with ZFP mutations could help flag those at higher risk of treatment resistance, allowing for earlier monitoring and potentially more effective treatment strategies.
This discovery not only provides a deeper understanding of cancer's ability to spread and resist treatment but also highlights the potential for new treatments that target ZFP36L2. The research team is now actively pursuing the development of therapies that could disrupt ZFP, offering a promising avenue for cancer treatment.
